Toxoplasma histone acetylation remodelers as novel drug targets

Laura Vanagas, Victoria Jeffers, Silvina S. Bogado, Maria C. Dalmasso, William Sullivan, Sergio O. Angel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Toxoplasma gondii is a leading cause of neurological birth defects and a serious opportunistic pathogen. The authors and others have found that Toxoplasma uses a unique nucleosome composition supporting a fine gene regulation together with other factors. Post-translational modifications in histones facilitate the establishment of a global chromatin environment and orchestrate DNA-related biological processes. Histone acetylation is one of the most prominent post-translational modifications influencing gene expression. Histone acetyltransferases and histone deacetylases have been intensively studied as potential drug targets. In particular, histone deacetylase inhibitors have activity against apicomplexan parasites, underscoring their potential as a new class of antiparasitic compounds. In this review, we summarize what is known about Toxoplasma histone acetyltransferases and histone deacetylases, and discuss the inhibitors studied to date. Finally, the authors discuss the distinct possibility that the unique nucleosome composition of Toxoplasma, which harbors a nonconserved H2Bv variant histone, might be targeted in novel therapeutics directed against this parasite.

Original languageEnglish
Pages (from-to)1189-1201
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume10
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Toxoplasma
Acetylation
Histones
Histone Acetyltransferases
Histone Deacetylases
Nucleosomes
Post Translational Protein Processing
Pharmaceutical Preparations
Parasites
Biological Phenomena
Antiparasitic Agents
Histone Deacetylase Inhibitors
Chromatin
Gene Expression
DNA
Genes
Therapeutics

Keywords

  • acetylation
  • HATs
  • HDACi
  • HDACs
  • histone
  • therapy
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

Vanagas, L., Jeffers, V., Bogado, S. S., Dalmasso, M. C., Sullivan, W., & Angel, S. O. (2012). Toxoplasma histone acetylation remodelers as novel drug targets. Expert Review of Anti-Infective Therapy, 10(10), 1189-1201. https://doi.org/10.1586/eri.12.100

Toxoplasma histone acetylation remodelers as novel drug targets. / Vanagas, Laura; Jeffers, Victoria; Bogado, Silvina S.; Dalmasso, Maria C.; Sullivan, William; Angel, Sergio O.

In: Expert Review of Anti-Infective Therapy, Vol. 10, No. 10, 10.2012, p. 1189-1201.

Research output: Contribution to journalArticle

Vanagas, L, Jeffers, V, Bogado, SS, Dalmasso, MC, Sullivan, W & Angel, SO 2012, 'Toxoplasma histone acetylation remodelers as novel drug targets', Expert Review of Anti-Infective Therapy, vol. 10, no. 10, pp. 1189-1201. https://doi.org/10.1586/eri.12.100
Vanagas, Laura ; Jeffers, Victoria ; Bogado, Silvina S. ; Dalmasso, Maria C. ; Sullivan, William ; Angel, Sergio O. / Toxoplasma histone acetylation remodelers as novel drug targets. In: Expert Review of Anti-Infective Therapy. 2012 ; Vol. 10, No. 10. pp. 1189-1201.
@article{66f44d09eabb42ce9a60c764cc1fdff2,
title = "Toxoplasma histone acetylation remodelers as novel drug targets",
abstract = "Toxoplasma gondii is a leading cause of neurological birth defects and a serious opportunistic pathogen. The authors and others have found that Toxoplasma uses a unique nucleosome composition supporting a fine gene regulation together with other factors. Post-translational modifications in histones facilitate the establishment of a global chromatin environment and orchestrate DNA-related biological processes. Histone acetylation is one of the most prominent post-translational modifications influencing gene expression. Histone acetyltransferases and histone deacetylases have been intensively studied as potential drug targets. In particular, histone deacetylase inhibitors have activity against apicomplexan parasites, underscoring their potential as a new class of antiparasitic compounds. In this review, we summarize what is known about Toxoplasma histone acetyltransferases and histone deacetylases, and discuss the inhibitors studied to date. Finally, the authors discuss the distinct possibility that the unique nucleosome composition of Toxoplasma, which harbors a nonconserved H2Bv variant histone, might be targeted in novel therapeutics directed against this parasite.",
keywords = "acetylation, HATs, HDACi, HDACs, histone, therapy, Toxoplasma gondii",
author = "Laura Vanagas and Victoria Jeffers and Bogado, {Silvina S.} and Dalmasso, {Maria C.} and William Sullivan and Angel, {Sergio O.}",
year = "2012",
month = "10",
doi = "10.1586/eri.12.100",
language = "English",
volume = "10",
pages = "1189--1201",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Toxoplasma histone acetylation remodelers as novel drug targets

AU - Vanagas, Laura

AU - Jeffers, Victoria

AU - Bogado, Silvina S.

AU - Dalmasso, Maria C.

AU - Sullivan, William

AU - Angel, Sergio O.

PY - 2012/10

Y1 - 2012/10

N2 - Toxoplasma gondii is a leading cause of neurological birth defects and a serious opportunistic pathogen. The authors and others have found that Toxoplasma uses a unique nucleosome composition supporting a fine gene regulation together with other factors. Post-translational modifications in histones facilitate the establishment of a global chromatin environment and orchestrate DNA-related biological processes. Histone acetylation is one of the most prominent post-translational modifications influencing gene expression. Histone acetyltransferases and histone deacetylases have been intensively studied as potential drug targets. In particular, histone deacetylase inhibitors have activity against apicomplexan parasites, underscoring their potential as a new class of antiparasitic compounds. In this review, we summarize what is known about Toxoplasma histone acetyltransferases and histone deacetylases, and discuss the inhibitors studied to date. Finally, the authors discuss the distinct possibility that the unique nucleosome composition of Toxoplasma, which harbors a nonconserved H2Bv variant histone, might be targeted in novel therapeutics directed against this parasite.

AB - Toxoplasma gondii is a leading cause of neurological birth defects and a serious opportunistic pathogen. The authors and others have found that Toxoplasma uses a unique nucleosome composition supporting a fine gene regulation together with other factors. Post-translational modifications in histones facilitate the establishment of a global chromatin environment and orchestrate DNA-related biological processes. Histone acetylation is one of the most prominent post-translational modifications influencing gene expression. Histone acetyltransferases and histone deacetylases have been intensively studied as potential drug targets. In particular, histone deacetylase inhibitors have activity against apicomplexan parasites, underscoring their potential as a new class of antiparasitic compounds. In this review, we summarize what is known about Toxoplasma histone acetyltransferases and histone deacetylases, and discuss the inhibitors studied to date. Finally, the authors discuss the distinct possibility that the unique nucleosome composition of Toxoplasma, which harbors a nonconserved H2Bv variant histone, might be targeted in novel therapeutics directed against this parasite.

KW - acetylation

KW - HATs

KW - HDACi

KW - HDACs

KW - histone

KW - therapy

KW - Toxoplasma gondii

UR - http://www.scopus.com/inward/record.url?scp=84870617451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870617451&partnerID=8YFLogxK

U2 - 10.1586/eri.12.100

DO - 10.1586/eri.12.100

M3 - Article

C2 - 23199404

AN - SCOPUS:84870617451

VL - 10

SP - 1189

EP - 1201

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 10

ER -